Seres Therapeutics Inc (MCRB) Stock Could Soon Reward Patient Investors

Seres Therapeutics Inc (NASDAQ: MCRB) is -20.00% lower on its value in year-to-date trading and has touched a low of $0.91 and a high of $6.87 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MCRB stock was last observed hovering at around $15.59M in the last trading session, with the day’s loss setting it -14.56%.

Currently trading at $1.03, the stock is 26.21% and -91.00% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.6 and changing 1.12% at the moment leaves the stock Nov 02 BMO off its SMA200. MCRB registered -79.03% loss for a year compared to 6-month loss of -71.50%. The firm has a 50-day simple moving average (SMA 50) of $1.47 and a 200-day simple moving average (SMA200) of -$1.51.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a -7.44% gain in the last 1 month and extending the period to 3 months gives it a 7.69%, and is 1.82% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.13% over the week and 8.33% over the month.

Profit margin for the company is -111.03%. Distance from 52-week low is 23.08% and -83.70% from its 52-week high. The company has generated returns on investments over the last 12 months (-74.01%).

Seres Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.5 with sales reaching $350k over the same period.The EPS is expected to grow by 56.96% this year, but quarterly earnings will post 1,668.70% year-over-year. Quarterly sales are estimated to shrink -65.20% in year-over-year returns.

Seres Therapeutics Inc (MCRB) Top Institutional Holders

153 institutions hold shares in Seres Therapeutics Inc (MCRB), with institutional investors hold 80.67% of the company’s shares. The shares outstanding are 125.22M, and float is at 97.82M with Short Float at 15.94%. Institutions hold 75.27% of the Float.

The top institutional shareholder in the company is Flagship Pioneering Inc. with over 23.12 million shares valued at $25.89 million. The investor’s holdings represent 17.88% of the MCRB Shares outstanding. As of Sep 29, 2023, the second largest holder is FMR, LLC with 19.23 million shares valued at $21.54 million to account for 14.88% of the shares outstanding. The other top investors are State Street Corporation which holds 9.54 million shares representing 7.38% and valued at over $10.68 million, while Blackrock Inc. holds 6.13% of the shares totaling 7.92 million with a market value of $8.87 million.

Seres Therapeutics Inc (MCRB) Insider Activity

A total of 16 insider transactions have happened at Seres Therapeutics Inc (MCRB) in the last six months, with sales accounting for 8 and purchases happening 8 times. The most recent transaction is an insider sale by Shaff Eric D. ,the company’sCEO and President. SEC filings show that Shaff Eric D. sold 8,552 shares of the company’s common stock on Oct 30 at a price of $1.35 per share for a total of $11545.0. Following the sale, the insider now owns 0.12 million shares.

Seres Therapeutics Inc disclosed in a document filed with the SEC on Oct 30 that von Moltke Lisasold a total of 4,232 shares of the company’s common stock. The trade occurred on Oct 30 and was made at $1.35 per share for $5713.0. Following the transaction, the insider now directly holds 9513.0 shares of the MCRB stock.

Still, SEC filings show that on Oct 30, DesRosier Thomas (Chief Legal Officer and EVP) disposed off 4,156 shares at an average price of $1.35 for $5611.0. The insider now directly holds 113,891 shares of Seres Therapeutics Inc (MCRB).

Seres Therapeutics Inc (MCRB): Who are the competitors?

The company’s main competitors (and peers) include Xencor Inc. (XNCR) that is trading -46.09% down over the past 12 months.